AdvanDx Lands $8M for Series C
Ryan McBride8/18/09
AdvanDx, a maker of molecular diagnostics for infectious diseases, said today it has raised $8 million in new closing of its Series C round of financing, which first closed in 2007. The company, which has offices in Woburn, MA, and Vedbaek, Denmark, said the new funds came from two of its existing European investors, Scandinavian Life Science Venture and LD Pensions. AdvanDx plans to use the new funding for product development as well as global sales and marketing efforts.
